tality rate of 30%.' Some 60% of patients with conjunctival melanoma experience recurrences, 32% have more than one recurrence' and many patients with multiple recurrences finally undergo orbital exenteration due to unresectable tumours. ' This suggests that recurrent conjunctival melanomas become more aggressive over time. Primary acquired melanosis (PAM) of the conjunctiva is a potential precursor lesion ofconjunctival melanoma, and 50% of lesions with cytological atypia will ultimately progress to malignant melanoma. 4 While the presence ofepitheloid cells and histological patterns other than basal hyperplasia may be more common in atypical PAM giving rise to melanoma, little is known of other predictors of malignant transformation.4 It is conceivable that cell proliferation is more marked in atypical PAM that progresses to melanoma than in lesions that remain confined to the epithelium. In addition, if the aggressive behaviour of recurrent conjunctival melanoma correlates with increased cell growth, recurrent disease may be monitored by assessing cell proliferation.
The proliferative compartment may be assessed by the fraction of cells expressing the proliferating cell nuclear antigen (PCNA), a 36 kD nuclear protein associated with the S phase of the cell cycle.5 Previous studies indicate that the PC 10 monoclonal antibody directed against PCNA may be used to assess prognosis in conjunctival melanoma. 1  Female  39  68  3  No  Yes  Yes  2  Female  67  157  2  No  No  No  3  Female  41  79  7  Yes  Yes  No  4  Male  67  75  4  Yes  No  No  5  Male  66 ... ' and all completed the study. The median interval between early and late recurrences was 538 days (10th and 90th centiles, 227 and 1407 days, respectively).
of the average PC 10 count. The two tailed t test for paired data confirmed the absence of bias (p=0 33). The 95% CI of the difference in counts was -1513 to 5-7.
IMMUNOSTAINING
A strong granular staining pattern was evident in the nuclei of the PCNA postive tumours. In PAM lesions these cells appeared singly (fig 1) ; however, in melanomas PCNA positive cells appeared as small clusters (figs 2A and 2B) . A large proportion of cells also displayed weaker immunoreactivity, particularly cells undergoing mitosis, possibly due to dissolution of the nuclear membrane. Although considerable intratumoural heterogeneity was a common feature, PC 10 intra-nuclear immunoreactivity was present in all conjunctival melanomas.
Expression of p53 protein in melanomas was limited to small nodules or even single cells, which were surrounded by tumour cells without apparent immunoreactivity (fig 2C) . However, the staining pattern of the small number of p53 positive cells was almost always strong and granular. The BP53-12-1 antibody showed a more distinct staining pattern than the D07 or 1801 clones. In two conjunctival melanomas, only the BP53-12-1 antibody invoked a positive response. Staining with 3-amino-9-ethylcarabazole produced a red colour that could be easily differentiated from melanin. the detection of proliferating melanocytes by staining with PC10 may be used to predict which lesions that are likely to undergo malignant transformation. In this study the median time interval between a confirmed diagnosis of atypical PAM and subsequent development of melanoma was three years; this interval was 2-5 years in a previous report.20 In the present study patients with atypical PAM who did not develop melanoma were followed for four years and it is unlikely that these patients will develop melanoma.
Most conjunctival melanomas with multiple recurrences ultimately require orbital exenteration,3 and may become more aggressive over time. As a high PC 10 count in conjunctival melanomas correlates with an adverse prognosis,' it is likely that the increase in PCI 0 counts over time in recurrent conjunctival melanoma reflects more aggressive behaviour. Four recurrences from two cases of conjunctival melanoma were available for study by immunohistochemistry. The limited data from these two tumours suggest that the PC 10 count increases sharply at exenteration and while further studies are needed to elucidate the clinical importance of the increase in cell proliferation over time, PC 10 counts may be used to monitor recurrent conjunctival melanoma. In the event of a significant increase in the proliferating cell count, aggressive therapy may have to be undertaken.
The epitope recognised by PC10 is stable for most fixation periods used for routine specimens.2' However, archival material may have been fixed for prolonged periods of time, which may result in a curtailed staining pattern. Recent data indicate that heating tissue sections in a microwave oven in an antigen retrieval solution containing heavy metal salts or distilled water results in consistent staining patterns in specimens fixed in formalin for up to 24 months.2223 These findings were confirmed by our pilot study, using fixation periods of up to 14 days. We found that citrate buffer produced staining as satisfactory and reproducible as that obtained using a commercially available antigen retrieval solution (Biogenex).
In this study p53 positive and negative conjunctival melanomas had similar PC 10 counts. This is in agreement with a study by Barbareschi et al '6 The findings presented here suggest that p53 alterations are not significant events in the tumorigenesis of conjunctival melanoma. Furthermore, ifp53 mutation is indeed a significant event in the pathogenesis of conjunctival melanoma this would be expected to correlate with cell growth.36 The results of this study indicate that p53 positive conjunctival melanomas do not contain more proliferating cells than tumours completely lacking p53 immunoexpression.
In conclusion, examination of the expression of proliferating cells in atypical PAM may be used as an adjunct to predict which lesions will progress to melanoma. The increase in the number of proliferating cells over time in recurrent conjunctival melanomas probably reflects more aggressive behaviour and may be used to monitor recurrence. The absence of p53 expression in PAM and minimal staining of conjunctival melanomas did not correlate with cell growth, suggesting that alterations in the p53 tumour suppressor gene are uncommon and late events in conjunctival melanoma, and that p53 expression is unlikely to be a useful prognostic indicator. 
